Dated proof you called it early
Your name, reason, and the date stay on this page and on your profile, ready to send to anyone.
Startup
UNITY Biotechnology
Biotechnology company targeting aging-related diseases.
Nobody has vouched for UNITY Biotechnology yet
The first person to vouch is the scout. Everyone after adds their name and their reason.
Scouted by
Nobody yet
The first person to vouch for UNITY Biotechnology is its scout, and that stays on the record.
Vouched by
Open. Vouches appear here in the order they were made.
Believe in UNITY Biotechnology? Be its scout.
One reason, in your own words. It takes about two minutes.
Vouch for UNITY BiotechnologyWhat vouching gets you
The founders are told
They get your name and your reason, and can write back to you.
Coming soonYou may be invited in
If UNITY Biotechnology raises here, people who vouched may be invited to take part. Earlier vouches first.
Coming soonWho believed, and when
Each vouch on one line, from the first one to today, and how those people know the startup.
No vouches yet. The line starts on the day of the first one.
Why people vouch
Each person says how they know the startup and why they believe in it.
No reasons yet
Reasons appear here in the words of the people who gave them, scout first.
From the founders
This page has not been claimed
When the founders of UNITY Biotechnology claim it with a work email, their names and their reply to the people who vouched appear here. Claiming is coming soon.
About UNITY Biotechnology
UNITY Biotechnology, Inc. was founded in March 2009, originally named Forge, Inc. The company specializes in developing senolytic therapeutics, which are designed to eliminate senescent cells linked to aging and chronic diseases. UNITY went public in May 2018, raising $85 million and achieving a market capitalization of $700 million. Its lead product, UBX1325, is a small molecule targeting BCL-xL, aimed at treating retinal diseases such as Diabetic Macular Edema.
More startups in Longevity
StartupTransforming drug discovery with AI.
StartupOptimizing healthspan through preventive medicine.
StartupAeovian Pharmaceuticals develops selective mTORC1 inhibitors for rare and age-related diseases, led by AV078 for tuberous sclerosis complex.
StartupAgeX Therapeutics was a Michael West company developing induced tissue regeneration and cell therapies for age-related degenerative disease.
StartupAgelessRx is a telehealth provider of longevity prescriptions such as rapamycin and metformin that also sponsors decentralized longevity trials.
StartupAlkahest mines the plasma proteome for therapies and biomarkers of age-related disease, building on young-plasma research.
What you can do with UNITY Biotechnology
Two of these work today. The rest are on the way.
Vouch for UNITY BiotechnologySay why you believe in it. The first person to vouch is its scout, and that stays on the record.
Claim this page
Founders and team members confirm with a work email, then keep the page accurate.
Coming soonFollow UNITY Biotechnology
Get a note when it raises, launches, or joins a program.
Coming soonSend it to an investor
Pass it to investors who back this sector, with your reason attached.
Pro, coming soonAsk for an introduction
Reach the founders through someone who has vouched for them.
Coming soonIs this page right?How the research works